Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1Phase 1 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 9Breast 3Plasma cell 2Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × 1-dodecylpyridoxal × Breast × Clear all
NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Sun Yat-sen University

Phase 2 Active not recruiting
156 enrolled
Breast

Breast Neoplasms

NCT05346107 2022-04-26

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Xijing Hospital

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms

NCT00550771 2017-06-07

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

Merck Sharp & Dohme LLC

Phase 2 Completed
181 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡